Dr. Nikolai A. Podoltsev
Claim this profileYale University
Studies Leukemia
Studies Acute Myeloid Leukemia
6 reported clinical trials
27 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 positive
Philadelphia chromosome positive
2Acute Myeloid Leukemia
FLT3 positive
D835 positive
Affiliated Hospitals
Clinical Trials Nikolai A. Podoltsev is currently running
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
Crenolanib vs Midostaurin
for Acute Myeloid Leukemia
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.
Recruiting3 awards Phase 3
More about Nikolai A. Podoltsev
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Nikolai A. Podoltsev has experience with
- Venetoclax
- Methotrexate
- Vincristine Sulfate
- Cytarabine
- Dexamethasone
- Cyclophosphamide
Breakdown of trials Nikolai A. Podoltsev has run
Leukemia
Acute Myeloid Leukemia
Lymphoblastic Leukemia-Lymphoma
Lymphoid Leukemia
Chronic Myelomonocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nikolai A. Podoltsev specialize in?
Nikolai A. Podoltsev focuses on Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Leukemia has involved BCR-ABL1 positive patients, or patients who are Philadelphia chromosome positive.
Is Nikolai A. Podoltsev currently recruiting for clinical trials?
Yes, Nikolai A. Podoltsev is currently recruiting for 5 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Nikolai A. Podoltsev has studied deeply?
Yes, Nikolai A. Podoltsev has studied treatments such as Venetoclax, Methotrexate, Vincristine Sulfate.
What is the best way to schedule an appointment with Nikolai A. Podoltsev?
Apply for one of the trials that Nikolai A. Podoltsev is conducting.
What is the office address of Nikolai A. Podoltsev?
The office of Nikolai A. Podoltsev is located at: Yale University, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.